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The preferential proliferation of cancer cells in the bone microenvironment is poorly characterised. Expression pattern of bone
marrow and other organ microenvironment in contact with osteolytic (Walker W256) and osteoblastic (MatLyLu MLL) metastases
were investigated. Fisher and Copenhagen rats received, respectively, W256 and MLL cells injection. Bone and soft tissues were
analysed by immunochemistry for DKK1, cathepsin K, RANKL, MCSF or IL6 expression. Tartrate-resistant acid phosphatase (TRAcP)-
positive cells were detected by a histoenzymatic technique. In bone, expressions of MCSF and DKK1 were shown in stromal cells of
the bone marrow, in contact with metastatic foci of both tumours. Many stromal cells were found RANKL positive in the vicinity of
the tumours. Cells expressing cathepsin K and multinucleated TRAcPþ cells were found in direct contact with trabeculae but also in
bone marrow spaces near metastatic cells. In extraosseous tumours, cells in contact with malignant cells did not expressed DKK1,
MCSF, cathepsin K and IL6. Some RANKLþ cells were found in the periphery of subcutaneous tumours but may represent
Langerhans cells. Abnormal presence of TRAcPþ cells was never observed in the vicinity of malignant cells. Interaction between
stromal and cancer cells induces the expression on the formers of characteristics leading to osteoclastogenesis only in the bone
microenvironment.
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Bone is a preferential site for metastasis in different types of
cancer. Bone metastases induce an increased morbidity (pain,
fractures, nerve compression, hypercalcaemiay) and compromise
the long-term survival. They occur in approximately 65–75% of
patients with an advanced breast or prostate cancer and 15–40%
of patients with a carcinoma of the lung, bladder, skin or kidney.
The median survival after first recurrence of breast cancer in bone
is 20 months (Coleman, 2001). Once a tumour has metastasised to
bone, it is virtually incurable and only palliative therapies can be
proposed (Mundy, 1997).
Interactions between the bone marrow environment and
cancer cells were first advocated by Paget, who described
them as ‘the seed and the soil’ theory (cited by Guise and Mundy,
1998): bone provides the ‘fertile soil’ in which certain cancer
cell (‘seeds’) find favourable conditions for growth. Mineralised
bone matrix is known to represent a rich storehouse of growth
factors that are mobilised by osteoclastic resorption and become
active in the local microenvironment. The release of these
growth factors constitutes one of the key mechanisms in the
bone remodelling allowing the physiological coupling between
osteoblasts (the bone forming cells) and the osteoclasts (bone-
resorbing cells) (Mundy et al, 2001). When localised in the marrow
spaces, tumour cells, in turn, secrete additional factors that
interfere with bone remodelling leading to tissular changes that
characterise the osteolytic or osteoblastic expression of the
metastases. Thus, local interactions between tumour and bone
cells form a vicious cycle that underlies the development of skeletal
metastases. During the last decade, it has become evident that
interactions between tumour and bone cells may change the
phenotype of both populations.
Breast and prostate cancer are the two tumour types that most
commonly metastasise to bone. On one hand, bone has
characteristics that allow the selective homing of tumour cells:
(1) a release of attractive molecules for these particular types of
cancer (stromal cell-derived factor-1, epidermal growth factor,
collagen degradation products, low glycosylated osteonectiny)
inducing specific chemotaxis (Cooper et al, 2003); (2) the
expression of adhesion molecule on the endothelial surface of
bone marrow capillaries (due to a variety of integrins such as a4b1,
a5b1, avb3, avb5) (Roodman, 2003); (3) appropriate growth
factors and extracellular matrix proteins present in the bone
marrow microenvironment (parathyroid hormone-related protein
(PTHrP), tumour growth factor beta (TGF-b), vascular endo-
thelium growth factor (VEGF)y) (Woodhouse et al, 1997; Guise
and Mundy, 1998; Keller et al, 2001). On the other hand, these
peculiar tumour cells express proteins that favour propensity to
migrate and anchor in bone: this includes chemotaxis (CXCR4)
(Muller et al, 2001), extravasation and bone marrow homing
(integrins, E-cadherin) (Woodhouse et al, 1997), pericellular
proteolysis and invasion (MMPs and ADAMs) (Woodhouse et al,
1997; Zigrino et al, 2005), angiogenesis (Woodhouse et al, 1997),
osteoclastogenesis (Roodman, 2004), growth factor regulation
(follistatin) (Risbridger et al, 2001; Reis et al, 2004) and
extracellular matrix alteration (proteoglycan-1) (Timar et al,
2002). A multigenic study of breast cancer metastasis to bone
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shas provided evidences for a causal role of IL-11, connective tissue-
derived growth factor (CTGF) and CXCR4, along with osteopontin
in osteolytic metastases. The combined overexpression of these
genes gives the transfected cells a metastatic activity close to that of
the highly aggressive cell populations endogenously expressing the
entire bone metastasis gene set (Kang et al, 2003).
Bone metastases are commonly characterised as osteolytic or
osteoblastic from a radiological point of view. This represents two
extremes of a continuum in which dysregulation of the normal
bone remodelling process occurs and alters bone mass and bone
microarchitecture. Breast cancer is most often associated with
osteolytic metastases, whereas osteoblastic metastases are common
in prostate cancer. Osteolytic lesions are due to a marked increase
in osteoclast number with a reduced osteoblastic activity.
Parathyroid hormone-related protein is a major mediator between
tumour and bone cells and induces the osteolytic process through
the RANKL pathway (Guise, 2000). On the contrary, osteoblastic
metastases are characterised by a dramatic increase in osteoforma-
tion, but always possess a resorption component (Mundy, 2002;
Logothetis and Lin, 2005).
Most researches have focused on the interactions between
tumour cells and osteoclasts or osteoblasts. However, interactions
with surroundings cells have been poorly investigated. Because
osteoblast precursors are stromal cells (present in the marrow
spaces) that interact with haematopoietic osteoclast precursors via
the RANK/RANKL/osteoprotegerin system (Thomas et al, 1999),
the potential influence of stromal cells on metastatic cells needs to
be investigated.
The aim of this study was to induce metastases in the rat to
investigate the expression pattern of these key molecules in the
bone microenvironment and also in the stroma of other organs
invaded by a metastasis. Two cell lines known to induce either
osteolytic or osteoblastic metastases were used.
MATERIALS AND METHODS
Cell lines and culture conditions
Two malignant cell lines capable of inducing bone metastases were
used in the present study.
Walker 256/B cells The Walker 256/B (W256) cells (issued of a rat
mammary carcinoma) are associated with osteolytic metastases
(Wingen et al, 1986; Rizzoli and Fleisch, 1987; Blouin et al, 2005).
W256 cells (kindly provided by Pr R Rizzoli, Geneva, Switzerland)
were grown in Dulbecco’s modified Eagle’s medium (DMEM;
Eurobio, Les Ulis, France) containing 10% heat-inactivated fetal
calf serum (FCS; Seromed Biochrom, Berlin, Germany),
100UIml
 1 of penicillin (Eurobio), 100mgml
 1 of streptomycin
sulphate (Eurobio), 1% of non essential amino acids (NEAA;
Cambrex, Walkersville, MD, USA) and 1mM of sodium pyruvate
(Eurobio). Cells were cultured at 371C in a humidified incubator
with 5% CO2. To obtain cells with a bone trophicity, 10
7 cells were
serially passaged intraperitoneally at 7-day intervals in Fisher rats
to obtain malignant ascite.
MatLyLu cells The MatLyLu cell line is an androgen-indepen-
dent, highly metastatic and anaplastic tumour of rat origin, which
spreads to the lymph nodes and invariably to the lung. Metastases
are reported to be osteoblastic in the vertebrae (Vieweg et al,
1994). The MatLyLu tumour cell line was obtained from ECCAC
(European Collection of Animal Cell Cultures, Salisbury, Wiltshire,
UK). MatLyLu cells were grown in Roswell Park Memorial Institute
1640 medium (RPMI 1640; Eurobio) containing 10% heat-
inactivated fetal calf serum (FCS; Seromed Biochrom), 100UIml
 1
of penicillin (Eurobio), 100mgml
 1 of streptomycin sulphate
(Eurobio) and 250nM of dexamethasone (Sigma, Saint Quentin
Fallavier, France). Cells were cultured at 371C in a humidified
incubator with 5% CO2.
Animals
The Animal Care and Use committee at the University of Angers
approved all procedures. Nine female Fisher F344/NHsd rats
(Harlan, Gannat, France), 3 weeks old were maintained for
6 months in the local vivarium conditions (241C and a 12h
light/dark cycle). Nine female Copenhagen born from COP/NCrl
rats (Charles River, Sulzfeld, Germany), bred in our University
animal facilities were maintained for 6 months in the same
conditions. Rats were given a standard laboratory food (UAR,
Villemoison sur Orge, France) and water ad libitum.
F344 rats were anaesthetised with isoflurane (AErrane; Baxter
S.A, Belgium) and received an intracardiac injection of 10
7 W256
cells in 0.25ml saline. They also received intramuscular (quad-
riceps femoris) and subcutaneous (base of the neck) injection with
10
7 W256 cells.
Copenhagen rats were anaesthetised with isoflurane and
received an intracardiac injection of 3.25 10
4 MLL cells in
0.25ml saline. They also received intramuscular, intraliver,
intraspleen and subcutaneous injections with 3.25 10
4 MLL cells
in the same locations than above. For both types of rats, the cell
number to be injected was determined as the most appropriate in
preliminary experiments. Data were compared with results
obtained on control rats.
Rats were sacrificed by asphyxiation with CO2, 9 days (F344) or
15 days (COP) after the intracardiac injection of tumour cells.
These durations have been determined by preliminary studies and
were found sufficient to obtain bone metastases before animals
die from other tumour localisation. The hindlimbs were carefully
dissected; bones and other tissue samples (liver, spleen, brain,
subcutaneous and intramuscular nodules) were placed in a
formalin-alcohol-based fixative at þ41C during 24h.
Histological staining methods on paraffin sections
Paraffin sections (4mm) were deparaffinised and stained by
Haematoxylin Phloxine Saffron (HPS) as a standard tissue stain.
Immunohistochemistry was performed on femur and organs of six
F344 and six COP rats. Bone decalcification was done using a
ready-to-use decalcifying fluid according to the manufacturer’s
recommendations (Surgipath, Labonord, Templemars, France).
Bone and other tissues were then dehydrated, embedded in
paraffin and sectioned at 4mm. Antigen retrieval was performed by
bain-marie heating in a citrate buffer (pH 6). Immunochemistry
was performed using DAKOCYTOMATION procedure with the
Dako autostainer automat (Dako, Glostrup, Denmark). The
following proteins were traced using specific antibodies:
  Dickkopf-1 (Dkk-1) is an antagonist of the canonical Wnt
signalling by binding directly to the LDL receptor-related
protein 5/6 (LRP5/6). The interaction between DKK1 ant LRP5/6
induces an inhibition of bone formation (Johnson et al, 2004).
The reagent was a purified goat polyclonal antibody (Tebu-bio,
sc-14949) used at a dilution of 1:50. Positivity is characterised
by a cell membrane labelling.
  Interleukin 6 (IL-6) is a pleitropic cytokine. Its production by
bone marrow stromal cells enhances osteoclastogenesis (with
subsequent bone resorption) and tumour cell growth (Roodman,
2003). We used a purified goat polyclonal antibody (Tebu-bio,
sc-1265) at a dilution of 1:50. Positivity is characterised by a
cytoplasmic labelling.
  RANKL is produced by osteoblasts and stromal cells and
induces osteoclastogenesis by interacting with its receptor at the
osteoclastic surface (Roodman, 2003). We used a purified goat
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spolyclonal antibody (Tebu-bio, sc-7628) at a dilution of 1:200.
Positivity is characterised by a cell membrane labelling.
  Cathepsin K is a cysteine protease highly expressed by
osteoclasts and is implicated in the bone matrix collagen
breakdown (Yasuda et al, 2005). The purified goat polyclonal
antibody (Tebu-bio, sc-6507) was used at a dilution of 1:200.
Positivity is characterised by a cytoplasmic labelling.
  Macrophage-colony stimulating factor (M-CSF) is expressed by
stromal cells and osteoblasts. It is required together with
RANKL to induce the development of mature osteoclasts (Boyle
et al, 2003). The purified goat polyclonal antibody (Tebu-bio,
sc-1324) was used at a dilution of 1:200. Positivity is
characterised by a cytoplasmic labelling.
Control-positive tissues were obtained for each antibody.
Sections were counterstained with haematoxylin.
TRAcP cells detection
Tartrate-resistant acid phosphatase (TRAcP)-positive cells were
detected by a histoenzymatic technique in three F344 and three
COP rats. Tartrate-resistant acid phosphatase is a key enzyme
found in high level in osteoclasts; it is involved in the intracellular
degradation of collagen and noncollagenous proteins of the bone
matrix (Vaaraniemi et al, 2004). Tissues were embedded in
methylmethacrylate at 41C to maintain enzyme activity. Bone
samples were embedded undecalcified. Sections (7-mm-thick) were
cut dry on a heavy-duty microtome equipped with 501 tungsten
carbide knives (Leica Polycut S, Rueil-Malmaison, France).
Tartrate-resistant acid phosphatase was revealed by a simulta-
neous coupling reaction using 1-naphtyl phosphate (Sigma-
Aldrich Chemical, Illkirsh, France) as substrate and Fast Violet B
as the diazonium salt. Sections were counterstained with
phosphomolybdic aniline blue (Chappard et al, 1983). Tartrate-
resistant acid phosphatase-positive cells appeared with a brownish
tint. Collagen fibres densely packed in the form of bone matrix or
in the tissue stroma appear with a blue tint.
RESULTS
Tumour growth in animals
F344 rats developed tumours at subcutaneous and intramuscular
site of injection. They also developed pulmonary, liver, brain and
bone tumours secondary to the intracardiac injection of W256
cells. In the femur, osteolytic foci were preferentially localised
below the growth cartilage and formed a large and irregular band
filled with malignant cells.
Copenhagen rats similarly developed tumours at subcutaneous,
intramuscular, liver and spleen sites of injection. They also
developed pulmonary and bone tumours after the intracardiac
injection. In the femur, focal areas of osteolysis were disseminated
all over the metaphysis. No osteosclerotic lesions were found.
Histological and immunohistochemical characteristics of
bone tumours
Tumour cells appeared most often as closely packed nodules ill-
demarcated from the haematopoeitic marrow. Some tumoral cells
were also found isolated in bone marrow. For both line cells,
tumour cells were large with a high nuclear/cytoplasmic ratio, they
exhibited proeminent nucleoli and a basophilic cytoplasm without
vacuoles. Numerous mitoses were observed. An increased
osteoclastogenesis was assessed in the immediate vicinity of the
tumour foci, leading to a dramatic increase of active erosion
surfaces and the resorption of complete bone trabeculae (Figure 1).
Siderophages (macrophages containing brownish cytoplasmic
particles) were frequently found, they reflect the necrotic and
remodelling steps occurring in the haematopoietic bone marrow
secondary to tumour invasion (Weinberg, 1983). These cells were
positive with the Perls reaction for iron. They are readily
distinguishable from immunolabelled cells under the microscope,
although they can appear with a similar intensity on black and
white microphotographs.
Both models exhibited the same immunohistochemical labelling
pattern: tumour cells never exhibited significant labelling for
M-CSF, Dkk-1, RANKL, IL-6 or cathepsin K (Figure 2). A strong
membrane expression of M-CSF was found in most bone marrow
stromal cells in contact with the metastatic foci. Dkk-1 was also
expressed at high levels in stromal cells and osteoblasts in contact
with metastatic foci in both models (Figure 2A). At distance, there
was no significant labelling for Dkk-1 in these cell populations.
Many stromal cells showed RANKL positivity in the vicinity of the
tumour (Figure 2C). RANKL labelling was also seen on osteoblasts
at distance of the tumour foci. These stromal cells (which were
labelled by Dkk1, M-CSF and RANKL) were found at distance from
trabeculae: they were mononucleated with often a large granular
cytoplasm; some of them appeared spindle-shaped. The IL-6
detection was not conclusive due to a nonspecific label induced by
the prior decalcification.
Two types of cells were found to express a faint and
homogenous cytoplasmic positivity for cathepsin K: typical
multinucleated osteoclasts at the surface of bone trabeculae and
multi- or mononucleated cells (either round or with cytoplasmic
branches) in the marrow spaces. These cells were mixed with
haematopoietic cells and were at a distance from bone surfaces
(Figure 2E); they concentrate in the close vicinity of the tumour
foci and at distance, on the contrary, they appeared scantily
distributed.
Two types of cells exhibited TRAcP positivity: multinucleated
cells apposed on trabeculae and either multi- or mononucleated
cells encountered in bone marrow spaces were; they were situated
far from trabecular surfaces and in the close vicinity of metastatic
cells, their density decreased at distance from tumoral foci
(Figure 3A).
Histological and immunohistochemical characteristics of
extraosseous tumours
Tumour nodules of both types of carcinomas were dense and well
delimited by a fibrous capsule. There were composed of a large
majority of tumour cells mixed with less numerous stromal cells.
Tumour cells showed a different aspect according to the metastatic
site: brain metastases were composed of spindle-shaped cells,
whereas in other sites, they appeared round or polygonal
(especially with Walker cells). For both line cells, tumour cells
T
Figure 1 Increased osteoclast number (arrows) and resorption lacunae
on trabeculae near metastatic foci of tumour cell (T) in bone (HPS staining).
Original magnification:  400.
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swere large with a high nucleocytoplasmic ratio; prominent nucleoli
were often present and the cytoplasms were devoid of vacuoles.
Numerous mitoses were observed, but small foci of necrosis were
also noted inside nodules.
Both tumour models exhibited the same immunohistochemical
labelling pattern: tumour cells never exhibited any significant
labelling for M-CSF, Dkk-1, RANKL, IL-6 and cathepsin K. Stromal
cells in contact with malignant cells did not express Dkk-1, M-CSF
and cathepsin K. At a distance from tumour foci, they also failed to
express these markers. IL-6 expression was found homogeneous in
the liver parenchyma with diffused granular cytoplasmic expres-
sion in the hepatocytes. The staining was found in all the liver
parenchyma and not restricted to the areas surrounding the
tumour. Few stromal cells were located around the tumoral foci
and did not exhibit IL-6 expression (Figure 3C). Some RANKL-
positive stromal cells were found at the periphery of subcutaneous
tumours. These mononucleated cells were round or stellate with an
abundant cytoplasm. No RANKLþ cells were found in any other
extraosseous site.
Tartrate-resistant acid phosphatase-positive cells were found
interspersed in the spleen parenchyma whether tumour cells were
present or not. These mononucleated TRAcPþ cells appeared
round with a large granular cytoplasm; the nucleus was ovoid or
reniform (Figure 3B). Tartrate-resistant acid phosphatase-positive
cells were never observed in the vicinity of malignant cells in any
other extraosseous metastases.
DISCUSSION
It is an oversimplification to consider only osteoblasts and
osteoclasts as the interacting partners of tumours cells in the
vicious cycle of cancer bone metastases. In addition to a variety of
matrix components, the tumour stroma contains a rich cell
population, which includes fibroblasts, smooth muscle cells,
endothelial cells, dendritic cells, macrophages and other inflam-
matory cells (Zigrino et al, 2005). This forms a network with a
complex crosstalk influencing cellular activities. For example,
various actors of the tumour microenvironment, such as
fibroblasts, immune cells and the extracellular matrix, influence
the ability of TGF-b to promote or suppress carcinoma progres-
sion and metastasis (Bierie and Moses, 2006). In a previous work,
we have shown an influence of the microenvironment on tumour
cell in the 5T2 multiple myeloma murine model, as a high bone
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Figure 2 (A) Dkk-1 expression in cells distant from tumoral foci (T) in bone with osteoblasts (arrow) and stromal cells (arrow head) exhibiting
membrane and cytoplasmic labelling. Other cells appearing in black at the top of the image are siderophages (S). (B) the negative control section stained
with the same concentration of control antibody, note that a group of osteoblasts (arrows) is negative. (C) RANKL expression near tumour foci in bone.
Osteoblasts (arrow) and stromal cells (arrow head) are RANKLþ. Tumour foci are RANKL negative. (D) The negative control section stained with the
same concentration of control antibody, note that a group of osteoblasts (arrow) is negative. (E) Cathepsin K expression near tumoral foci (T) in bone.
Cathepsin Kþ multi- and mononucleated cells (arrow head) have a diffuse and faint cytoplasmic labelling. Both can be found in marrow spaces at a distance
from bone surfaces. A siderophage (iron-loaded macrophage) is also evidenced (S). (F) The negative control section stained with the same concentration of
control antibody; note that an osteoclasts (arrow) is negative. For all images, the original magnification is  400.
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sremodelling (induced by ovariectomy) dramatically increased
tumour growth (Libouban et al, 2003). This altered microenviron-
ment was able to select a highly aggressive myeloma cell line
(Libouban et al, 2004). Others have also reported that parathyroid
hormone injection in athymic mice induced a preferential
localisation of PC-3 prostate cancer cells in bones (Schneider
et al, 2005).
Interactions of malignant cells with endothelial cells in bone
metastases have been previously investigated. van der Pluijm et al
(2001) observed significantly elevated mRNA levels for VEGF-A
and -B in bone metastases compared with soft tissue metastases
induced by the human breast cancer cells MDA-MB-231. Di
Raimondo et al (2000) similarly detected higher concentrations of
the angiogenic peptides (VEGF, bFGF (basic fibroblast growth
factor) and HGF (hepatocyte growth factor)) in bone marrow than
in the peripheral circulation of patients with multiple myeloma.
This suggests the specific induction within the bone microenvir-
onment of angiogenic factors, which allows the development of a
neovascular network favouring the tumour growth.
Interaction between tumour cells and other stromal components
also plays a major role in cancer progression. Cancer cells can alter
the surrounding connective tissues and modulate the metabolism
of fibroblasts, thus resulting in the production of a collagenous
stroma that supports the tumoral process. Fibroblast is a key
component of tumours, because it acquires a modified phenotype
similar to those associated with wound healing. Such ‘activated’
fibroblasts have been coined ‘carcinoma-associated fibroblasts’
(Kalluri and Zeisberg, 2006). Carcinoma-associated fibroblasts are
implicated in extracellular matrix production, which provides a
lattice that facilitates cancer progression; they are one of the main
sources of VEGF, thus providing more nutriment to the
metastastic cells (Kalluri and Zeisberg, 2006). Shimamura et al
(2005) have investigated the microenvironment of osteolytic
metastases caused by MDA-MB 231 breast carcinoma cells
in nude mice. At 2 weeks after an intracardiac injection with
MDA-MB 231 cells, foci of tumour cells were associated with
osteoclastogenesis together with angiogenesis related to intense the
expression of VEGF (Shimamura et al, 2005). In our study, we have
also found specific modifications in the bone microenvironment
around the tumour foci with expression of M-CSF, Dkk-1 and
RANKL in non-osteoblastic cells. Moreover, mononucleated
TRAcPþ cells were also encountered in bone marrow spaces far
from trabecular surfaces. This denotes an increased induction of
osteoclast precursors, as mononuclear TRAcPþ cells in the bone
marrow are a source for mature multinucleated osteoclasts (Baron
et al, 1986). These mononucleated TRAcPþ cells expressed
cathepsin K and were found in medullar spaces at distance from
bone surfaces. All these cells were found with a density decreasing,
as the distance from tumour cells increased. It is probable that a
gradient of cytokines released from malignant cells can explain
this finding. Tumour cells produce a variety of soluble factors
(PTHrP, TGF-b, IGF, endothelin-1y) that are employed as a
paracrine communication system with surrounding cells or as an
autocrine regulation system (Guise and Mundy, 1998; Guise et al,
2003; Lee et al, 2003). W256 and MatLyLu cells are unable to
resorb bone by themselves and have been reported to produce high
levels of PTHrP, which promotes osteoclastogenesis (Rizzoli and
Fleisch, 1987; Rabbani et al, 1999).
The stromal expression of important cytokines involved in the
bone remodelling was found altered only when metastatic cells
were developing in a bony microenvironment. No expression of
these cytokines could be observed in the tumour stroma when
metastastic cells had developed in other organs. The few RANKLþ
cells found at the periphery of subcutaneous tumours were
probably Langerhans cells. Tartrate-resistant acid phosphatase-
positive cells encountered both in invaded and non-invaded
spleens probably corresponded to activated macrophages, a
condition previously noted by others (Hayman et al, 2000).
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Figure 3 (A) Multinucleated TRAcPþ cells in bone are apposed on trabeculae. In bone marrow spaces, multi- (arrow) and mononucleated (arrow head)
TRAcPþ cells are also encountered far from trabecular surfaces and near tumour cells (T) (undecalcified plastic section). Original magnification:  200.
(B) TRAcPþ cells are found interspersed in the spleen parenchyma in the presence or not of tumour cells. These mononucleated TRAcPþ cells are round
with a large cytoplasm in the red pulp. Note that the white pulp is negative (M¼Malpighi corpuscle). (plastic section). Original magnification:  50. (C) IL-6
expression in the liver. Note that tumoural foci (T) are negative, whereas hepatocytes show a homogeneous granular cytoplasmic expression. Original
magnification:  50. (D) The negative control section stained with the same concentration of control antibody, note that an osteoclasts (arrow) is negative.
Original magnification:  50.
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sTartrate-resistant acid phosphatase-positive cells were previously
observed in the stroma of bone tumours (Yam et al, 1987).
Tartrate-resistant acid phosphatase-positive osteoclast-like cells
are also observed in giant cells tumours that can develop within
bone (and cause osteolytic lesions) or soft tissues (Teot et al,
1996). In this tumour, the malignant component is of fibroblastic
origin and express RANKL, which provokes osteoclastogenesis
(Murata et al, 2005). In our models, stromal cells were able to
express RANKL and to induce osteoclastogenesis only in the bone
compartment.
Tumour cells do not have the same cytokine pattern of expression
according to their location and can modulate it depending on the
surrounding stromal cells. For example, breast cancer cells have an
increased expression of PTHrP in bone metastases when compared
with other sites (Mundy, 2002). As a consequence, the microenviron-
ment can also influence the tumour cells: Walker cells acquired a
spindle shape only when located in brain metastases, whereas they
appeared round or polygonal in other sites. The difference may
also be supported by soft tissue stromal cells, which can have
different surface receptors than bone stromal cells, making them
unable to respond to tumour cell stimulation.
In conclusion, interaction between stromal and cancer cells
alters the expression of the former leading to osteoclastogenesis in
the bone microenvironment. These modifications allow the growth
of the metastases in a convenient microenvironment. It thus
explains the preferential localisation observed in our bone
metastasis models. The major role of osteoclasts and osteoblasts
in bone metastasis formation has led to underestimate the critical
function of microenvironment in metastasis growth.
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